Symposium | Looking to the future of bispecific antibodies in MM, and panelist Q&A

The Multiple Myeloma Hub virtual symposium held on March 11, 2024,“Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” concluded by looking to the future of T-cell engagers in multiple myeloma, delivered by chair Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US.

Lonial shared his future perspectives for the treatment of relapsed/refractory multiple myeloma, including strategies for managing resistance to B-cell maturation antigen, alternative treatments for anti-BCMA exposed patients, and the potential of cereblon E3 ligase modulators (Figure 1).

Figure 1. Novel CELMoD agents in development*

CELMoD, cereblon E3 ligase modulators; CRBN, cereblon; MM, multiple myeloma.
*Data from Rajkumar, et al.¹; Facon, et al.²; Durie, et al.³; Ito and Handa.⁴; Matyskiela, et al.⁵; Hansen, et al.^6
†Iberdomide (IBER; CC-220) and mezigdomide (CC-92480) are investigational products that are currently not approved by any regulatory agency. 

Q&A session

This symposium closed with a panel Q&A session with live audience participation. Our panelists shared their perspectives on key topics including health-related quality of life in patients treated with bispecific antibodies, highlighting the impact of reduced dosing frequencies, as well as subcutaneous versus intravenous administration, on the patient experience.

This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.